press releases

 
AROMICS receives 1 Million Euros to advance in its therapy for cancer

February 2019

El mundo

AROMICS receives 1 Million Euros to advance in its therapy for cancer

Malignant Mesothelioma is an aggressive, poor prognosis and highly refractory cancer. It is also known as the "asbestos cancer", as this mineral widely used at the industrial settings over the past century, is the main origin of the tumour. The published new established an important milestone for AROMICS. The company has received EU H2020 funding for advancing in a new therapy to treat this devastating cancer.  

 
AROMICS receives 1 Million Euros to advance in its therapy for cancer

February 2019

Expansión

AROMICS receives 1 Million Euros to advance in its therapy for cancer

The European Commission has allocated, through the H2020-EIC-SMEInst-2018-2020-Phase 2 program,  a total of 1,085.659€ to the BERMES project of Aromics, the objective of which is to complete the regulatory pre-clinical stage in order to begin studies in humans of the drug NAX035 for malignant mesothelioma, an aggressive and highly resistant cancer linked to asbestos exposure.  

 
AROMICS develops a novel therapy for malignant mesothelioma

February 2019

El Periodico

AROMICS develops a novel therapy for malignant mesothelioma

AROMICS is developing a novel therapy for the treatment of rare and highly refractory cancers like malignant mesothelioma, an asbestos-related cancer. European Commission through its SME instrument at Horizon 2020 program is supporting the company in the development.

 
AMMIC: New platform for Catalan companies and organizations accelerates drug R&D for minority diseases

March 2018

La Vanguardia

AMMIC: New platform for Catalan companies and organizations accelerates drug R&D for minority diseases

Acceleradora en Malalties Minoritàries de Catalunya (AMMIC) is part of the RIS3CAT community coordinated by Biocat. It is led by IUCT and other members include VHIR, Esteve, Aromics, BCN Peptides, Minoryx, Aniling and Qgenomics After its first year of work, the AMMIC project has seen its first scientific results, including the launch of a phase II/III study in Adrenoleukodystrophy, the preclinical assessment with animal models of the efficacy of three new candidate molecules to treat Malignant pleural mesothelioma, Pediatric Rhabdomyosarcoma and Myotonic dystrophy type 1. Follow the new here

 
Asbestos and cancer

December 2017

El Periodico

Asbestos and cancer

Malignant Mesothelioma is an aggresive, poor prognosis and highly refractory cancer. It is also known as the "asbestos cancer", as this mineral widely used at the industrial settings over the past century, is the main origin of the tumor. The published new established an important milestone: first sentence of a judge admiting the damage induced by asbestos to neighbours that simply lived closed to the area of influence of an asbestos' manufacture industry.